Omeros Gets FDA Approval of Yartemlea
By Colin Kellaher
Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants.
Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the activation of the lectin pathway of complement.
The Seattle biopharmaceutical company said Yartemlea selectively inhibits the effector enzyme of the lectin pathway, blocking pathway activation while preserving classical and alternative complement functions important for host defense.
Omeros said the FDA green light makes Yartemlea the first and only approved lectin pathway inhibitor, adding that it is finalizing preparations for its U.S. product launch next month.
Trading in shares of Omeros, which closed Tuesday at $8.75, was halted premarket on Wednesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 24, 2025 09:27 ET (14:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States